Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma.

Clark JM, Kelley B, Titze J, Fung H, Maciejewski J, Nathan S, Rich E, Basu S, Kaufman HL.

Oncology. 2013;84(2):123-6. doi: 10.1159/000342764. Epub 2012 Dec 7.

PMID:
23235386
3.

Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.

Lissoni P, Bordin V, Vaghi M, Fumagalli L, Bordoni A, Mengo S, Bucovec R, Fumagalli E, Malugani F, Ardizzoia A, Giani L, Gardani GS, Tancini G.

Anticancer Res. 2002 Mar-Apr;22(2B):1061-4.

PMID:
12168901
4.

The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma.

Hughes T, Klairmont M, Broucek J, Iodice G, Basu S, Kaufman HL.

Cancer Immunol Immunother. 2015 Apr;64(4):459-65. doi: 10.1007/s00262-014-1652-6. Epub 2015 Jan 22.

5.

Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2.

Spanknebel K, Cheung KY, Stoutenburg J, Hurst-Wicker K, Hesdorffer C, Rn GD, Kaufman AH.

Ann Surg Oncol. 2005 May;12(5):381-90. Epub 2005 Apr 4.

PMID:
15915372
6.

[Systemic immunotherapy of metastatic renal cell carcinoma and long-term outcome].

Brinkmann OA, Roigas J, Hertle L.

Urologe A. 2002 May;41(3):231-8. German.

PMID:
12132272
8.

Long-term survival in patients with metastatic renal cell carcinoma treated with continuous intravenous infusion of recombinant interleukin-2: the experience of a single institution.

Libra M, Talamini R, Crivellari D, Buonadonna A, Freschi A, Stefanovski P, Berretta M, De Cicco M, Balestreri L, Merlo A, Volpe R, Galligioni E, Sorio R.

Tumori. 2003 Jul-Aug;89(4):400-4.

PMID:
14606643
9.

Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.

Henriksson R, Nilsson S, Colleen S, Wersäll P, Helsing M, Zimmerman R, Engman K.

Br J Cancer. 1998 Apr;77(8):1311-7.

10.

Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.

de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH.

Clin Cancer Res. 2000 Apr;6(4):1267-72.

11.
12.

Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-alpha, and tegafur-uracil: a single-institution experience.

Kobayashi M, Ikeda H, Nukui A, Suzuki K, Sugaya Y, Yuzawa M, Morita T.

Int J Clin Oncol. 2008 Jun;13(3):257-62. doi: 10.1007/s10147-007-0752-0. Epub 2008 Jun 14.

PMID:
18553237
13.
14.

Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.

Miyake H, Kurahashi T, Takenaka A, Inoue TA, Fujisawa M.

Urol Oncol. 2009 Nov-Dec;27(6):598-603. doi: 10.1016/j.urolonc.2008.07.023. Epub 2008 Sep 25.

PMID:
18818106
15.

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.

Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL.

J Clin Oncol. 2006 Mar 1;24(7):1169-77.

PMID:
16505437
16.
17.

Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.

Acquavella N, Kluger H, Rhee J, Farber L, Tara H, Ariyan S, Narayan D, Kelly W, Sznol M.

J Immunother. 2008 Jul-Aug;31(6):569-76. doi: 10.1097/CJI.0b013e318177a4ba.

PMID:
18528297
18.

Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.

Majhail NS, Wood L, Elson P, Finke J, Olencki T, Bukowski RM.

Clin Genitourin Cancer. 2006 Jun;5(1):50-6.

PMID:
16859579
19.

Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.

Negrier S, Maral J, Drevon M, Vinke J, Escudier B, Philip T.

Cancer J Sci Am. 2000 Feb;6 Suppl 1:S93-8.

PMID:
10685667
20.

Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.

Garcia JA, Mekhail T, Elson P, Wood L, Bukowski RM, Dreicer R, Rini BI.

BJU Int. 2012 Jan;109(1):63-9. doi: 10.1111/j.1464-410X.2010.10011.x. Epub 2011 Jan 18.

Supplemental Content

Support Center